Dawn R Cochrane
Overview
Explore the profile of Dawn R Cochrane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
2000
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gibbard E, Cochrane D, Sowamber R, Huvila J, Nitschke A, Greening K, et al.
Int J Gynecol Cancer
. 2025 Feb;
35(2):101635.
PMID: 39921960
Objective: Oral contraceptives reduce ovarian cancer risk, but the mechanism of risk reduction is not understood. We examined whether oral contraceptive pill (OCP) use influences p53 signatures, which are putative...
2.
Ji J, Hoang L, Cochrane D, Lum A, Senz J, Farnell D, et al.
J Pathol
. 2024 Aug;
264(2):160-173.
PMID: 39096103
Clear cell ovarian carcinoma (CCOC) is an aggressive malignancy affecting younger women. Despite ovarian cancer subtypes having diverse molecular and clinical characteristics, the mainstay of treatment for advanced stage disease...
3.
Jamieson A, Sobral de Barros J, Cochrane D, Douglas J, Shankar S, Lynch B, et al.
Clin Cancer Res
. 2024 Mar;
30(11):2461-2474.
PMID: 38536067
Purpose: Shallow whole-genome sequencing (sWGS) can detect copy-number (CN) aberrations. In high-grade serous ovarian cancer (HGSOC) sWGS identified CN signatures such as homologous recombination deficiency (HRD) to direct therapy. We...
4.
Ji J, Cochrane D, Negri G, Colborne S, Spencer Miko S, Hoang L, et al.
J Pathol
. 2022 Aug;
258(4):325-338.
PMID: 36031730
Clear cell ovarian carcinoma (CCOC) is the second most common subtype of epithelial ovarian carcinoma. Late-stage CCOC is not responsive to gold-standard chemotherapy and results in suboptimal outcomes for patients....
5.
Pilsworth J, Todeschini A, Neilson S, Cochrane D, Lai D, Anttonen M, et al.
J Pathol
. 2021 Aug;
255(3):225-231.
PMID: 34338304
A recurrent mutation in FOXL2 (c.402C>G; p.C134W) is present in over 95% of adult-type granulosa cell tumours (AGCTs). In contrast, various loss-of-function mutations in FOXL2 lead to the development of...
6.
Huvila J, Cochrane D, Ta M, Chow C, Greening K, Leung S, et al.
J Pathol Clin Res
. 2021 Jun;
7(6):548-555.
PMID: 34138519
Ovarian carcinoma histotypes are distinct diseases with variable clinical outcomes and response to treatment. There is a need for new subtype-specific treatment modalities, especially for women with widespread and chemo-resistant...
7.
Pilsworth J, Cochrane D, Neilson S, Moussavi B, Lai D, Munzur A, et al.
J Pathol Clin Res
. 2021 Jan;
7(3):243-252.
PMID: 33428330
Adult-type granulosa cell tumors (aGCTs) account for 90% of malignant ovarian sex cord-stromal tumors and 2-5% of all ovarian cancers. These tumors are usually diagnosed at an early stage and...
8.
Gibbard E, Cochrane D, Pors J, Negri G, Colborne S, Cheng A, et al.
Hum Pathol
. 2020 Oct;
108:1-11.
PMID: 33121982
Mesonephric carcinomas (MEs) and female adnexal tumors of probable Wolffian origin (FATWO) are derived from embryologic remnants of Wolffian/mesonephric ducts. Mesonephric-like carcinomas (MLCs) show identical morphology to ME of the...
9.
Cochrane D, Campbell K, Greening K, Ho G, Hopkins J, Bui M, et al.
J Pathol
. 2020 Jul;
252(2):201-214.
PMID: 32686114
Endometrial carcinoma, the most common gynaecological cancer, develops from endometrial epithelium which is composed of secretory and ciliated cells. Pathologic classification is unreliable and there is a need for prognostic...
10.
Ji J, Cochrane D, Tessier-Cloutier B, Chen S, Ho G, Pathak K, et al.
Clin Cancer Res
. 2020 May;
26(16):4402-4413.
PMID: 32409304
Purpose: Many rare ovarian cancer subtypes, such as small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT), have poor prognosis due to their aggressive nature and resistance to standard platinum- and...